Work

Design of a Phase 2/3 Adaptive Trial Evaluating Inaxaplin in APOL1-Mediated Kidney Disease

Year: 2022

Type: article

Study design: Study Protocol

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.20223311s1181c

Authors: Ronald Falk, Laura Barisoni, David Friedman, Debbie Gipson, Michael Lipkowitz, Akinlolu Ojo, Martin Pollak, Madalina Chirieac, Mariana Faria-Urbina, Yang Song, George Manos, Anna Ferreira, Ogo I. Egbuna, Glenn Chertow

Institutions: University of North Carolina at Chapel Hill, Duke University, Beth Israel Deaconess Medical Center, University of Michigan, Georgetown University, University of Kansas, University of Kansas Medical Center, Vertex Pharmaceuticals (United States), Stanford Medicine, Stanford University

Language: English

Topic: Renal Diseases and Glomerulopathies

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396990024

FWCI: 0.159

Cites:

Cited by: 1

Related to: 10